Multiple Sclerosis Clinical Trials
By Naomi Kresge
20 January 2010
"Jan. 20 (Bloomberg) -- The first oral medicines for multiple sclerosis from Novartis AG and Merck KGaA may offer patients who are willing to run the risk of infections and other side effects an easier route toward treating the debilitating neurological disease, according to three studies."
(The drugs are immunosuppressive.)
Read full article